ALLO-647 is an anti-CD52 monoclonal antibody which is designed to be part of the lymphodepletion regimen. ALLO-647 may reduce the likelihood of a patient’s immune system rejecting the engineered allogeneic T cells, and may create a window of persistence during which the engineered allogeneic T cells can actively target and destroy cancer cells.
SparkCures ID | 359 |
---|---|
Developed By | Allogene Therapeutics |
Generic Name | ALLO-647 |
Treatment Classifications | |
Treatment Targets |
|
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
There are no resources, links or videos to display for this treatment.